Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTX NASDAQ:CRVS NASDAQ:ETON NASDAQ:GOSS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.69-6.4%$1.79$0.22▼$3.83$124.62M1.194.67 million shs160,963 shsCRVSCorvus Pharmaceuticals$7.07-0.6%$5.89$2.54▼$10.00$519.04M0.57793,725 shs23,143 shsETONEton Pharmaceuticals$18.05-0.2%$18.15$7.58▼$23.00$472.43M1.16354,403 shs17,516 shsGOSSGossamer Bio$2.37-3.1%$2.52$0.66▼$3.60$535.48M1.942.39 million shs98,303 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-1.64%+16.88%-17.05%+216.90%+349.66%CRVSCorvus Pharmaceuticals+2.60%+1.86%+21.96%+70.50%+12.32%ETONEton Pharmaceuticals-8.04%-12.78%+2.44%+25.29%+126.00%GOSSGossamer Bio+7.02%+1.24%-29.48%+68.28%+152.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.69-6.4%$1.79$0.22▼$3.83$124.62M1.194.67 million shs160,963 shsCRVSCorvus Pharmaceuticals$7.07-0.6%$5.89$2.54▼$10.00$519.04M0.57793,725 shs23,143 shsETONEton Pharmaceuticals$18.05-0.2%$18.15$7.58▼$23.00$472.43M1.16354,403 shs17,516 shsGOSSGossamer Bio$2.37-3.1%$2.52$0.66▼$3.60$535.48M1.942.39 million shs98,303 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-1.64%+16.88%-17.05%+216.90%+349.66%CRVSCorvus Pharmaceuticals+2.60%+1.86%+21.96%+70.50%+12.32%ETONEton Pharmaceuticals-8.04%-12.78%+2.44%+25.29%+126.00%GOSSGossamer Bio+7.02%+1.24%-29.48%+68.28%+152.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 2.80Moderate Buy$2.8368.15% UpsideCRVSCorvus Pharmaceuticals 2.60Moderate Buy$13.7594.57% UpsideETONEton Pharmaceuticals 2.40Hold$29.6764.36% UpsideGOSSGossamer Bio 2.67Moderate Buy$8.50259.41% UpsideCurrent Analyst Ratings BreakdownLatest CGTX, ETON, GOSS, and CRVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025CRVSCorvus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.0010/13/2025CRVSCorvus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.0010/8/2025CGTXCognition TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CRVSCorvus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GOSSGossamer BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025ETONEton PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025CGTXCognition TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CRVSCorvus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GOSSGossamer BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AETONEton Pharmaceuticals$39.01M12.41N/AN/A$0.94 per share19.20GOSSGossamer Bio$114.70M4.69N/AN/A$0.13 per share18.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$33.97M-$0.67N/AN/AN/AN/A-251.23%-130.75%11/12/2025 (Estimated)CRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A36.10N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)Latest CGTX, ETON, GOSS, and CRVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CRVSCorvus Pharmaceuticals-$0.14N/AN/AN/AN/AN/A11/11/2025Q3 2025ETONEton Pharmaceuticals$0.13N/AN/AN/A$20.47 millionN/A11/6/2025Q3 2025GOSSGossamer Bio-$0.19N/AN/AN/A$6.32 millionN/A8/7/2025Q2 2025CGTXCognition Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/A8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A1.541.54CRVSCorvus PharmaceuticalsN/A8.918.91ETONEton Pharmaceuticals1.141.771.16GOSSGossamer BioN/A4.404.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%CRVSCorvus Pharmaceuticals46.64%ETONEton Pharmaceuticals27.86%GOSSGossamer Bio81.23%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics14.40%CRVSCorvus Pharmaceuticals31.30%ETONEton Pharmaceuticals14.89%GOSSGossamer Bio6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2073.52 million62.94 millionNot OptionableCRVSCorvus Pharmaceuticals3074.51 million51.19 millionOptionableETONEton Pharmaceuticals2026.82 million22.83 millionOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableCGTX, ETON, GOSS, and CRVS HeadlinesRecent News About These Companies3 Biotech Stocks That Could More Than Triple if Their Trials SucceedOctober 11 at 5:51 PM | msn.comAnalysts Set Gossamer Bio, Inc. (NASDAQ:GOSS) Target Price at $8.50October 10, 2025 | americanbankingnews.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Gossamer Bio (NASDAQ:GOSS)October 9, 2025 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Stock Price Down 5.6% - Time to Sell?October 6, 2025 | marketbeat.comGossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Rating of "Moderate Buy" from BrokeragesOctober 5, 2025 | marketbeat.comPlatinum Investment Management Ltd. Cuts Position in Gossamer Bio, Inc. $GOSSOctober 2, 2025 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Trading Down 5.1% - Time to Sell?September 30, 2025 | marketbeat.comCrinetics drug to challenge pharma ‘Goliaths’; FDA, ARPA move to speed gene therapiesSeptember 26, 2025 | biopharmadive.comBCrinetics drug to challenge pharma ‘Goliaths’; FDA, ARPA move to speed gene therapiesSeptember 26, 2025 | biopharmadive.comBGossamer Bio granted option to acquire RespiraSeptember 25, 2025 | thepharmaletter.comTGossamer Bio Enters Merger Agreement with RespiraSeptember 25, 2025 | tipranks.comRespira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapitalSeptember 25, 2025 | prnewswire.comGossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary HypertensionSeptember 25, 2025 | businesswire.comGossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib ProgressSeptember 23, 2025 | insidermonkey.comGossamer Bio (NASDAQ:GOSS) Shares Down 4% - Time to Sell?September 23, 2025 | marketbeat.comGoldman Sachs Group Inc. Buys 825,047 Shares of Gossamer Bio, Inc. $GOSSSeptember 23, 2025 | marketbeat.comGossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025September 22, 2025 | businesswire.comGossamer Bio (NASDAQ:GOSS) Stock Rating Lowered by Wall Street ZenSeptember 21, 2025 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Shares Gap Up - Still a Buy?September 18, 2025 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Trading Down 5% - Time to Sell?September 16, 2025 | marketbeat.comGossamer Bio (GOSS): Assessing Valuation After Encouraging Phase 2 Data and Analyst OptimismSeptember 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGTX, ETON, GOSS, and CRVS Company DescriptionsCognition Therapeutics NASDAQ:CGTX$1.68 -0.12 (-6.39%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Corvus Pharmaceuticals NASDAQ:CRVS$7.07 -0.04 (-0.60%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Eton Pharmaceuticals NASDAQ:ETON$18.05 -0.03 (-0.17%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Gossamer Bio NASDAQ:GOSS$2.37 -0.08 (-3.07%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
